Leukemias
(AML & ALL)
Allogeneic Transplantation Trials
COMIRB: 16-1762
Safety and Efficacy of Miltenyi CliniMACS® CD34 Reagent System for Transplant Protocol Utilizing Haploidentical CD34+ Selected Cells Combined with Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders
Principal Investigator: Jon Gutman
Eligibility: Ages ≥ 18 years; diagnosed with high risk hematologic disorders warranting stem cell transplant per institutional standard of care; adequate organ function; lack HLA-identical related donor and availability of at least one HLA-haploidentical related donor who is available to donate CD34+ cells
COMIRB: 20-1970
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)
PI: Jon Gutman
Eligibility: Ages ≥ 18 years for part 1; Ages ≥ 12 years for part 2; diagnosed with AML and be planning for allogeneic SCT or have received allogeneic SCT within the past 60 days; Karnofsky Performance Scale > 50 if ages ≥ 17 or > 40 if ages 12-16
COMIRB: 23-115
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
PI: Ajay Major
Eligibility: Ages ≥ 18; post alloSCT
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.